Replies to post #88680 on Biotech Values

[DewDiligence]

…therefore, I think docs are likely to wait for more data (including outcomes data).

No argument there—the disappointing sales numbers for Tekturna speak for themselves. However, if docs are waiting for “pure” hypertension outcomes data showing a reduction in mortality or MACE, they will be waiting a long time!

[DewDiligence]

CHMP approves NVS’ Rasilamlo (Rasilez+Amlodipine) for hypertension:

http://www.reuters.com/article/2011/02/18/norvartis-idUSLDE71H1ER20110218

In the US, this product was approved in Aug 2010 (#msg-53782319) and is called Tekamlo (Tekturna+Amlodipine). A 3-in-1 variation with HCTZ added was approved in Dec 2010 (#msg-58062858) and is called Amturnide (Amlodipine+Tekturna+Hydrochlorothiazide).

Standalone sales of Tekturna/Rasilez have been disappointing; maybe these combination products will be material contributors.